Distributor inventory | Tablet

Type 2 diabetes mellitus; used to improve blood glucose control in adults when diet and exercise alone or single therapy is insufficient.

Vildagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing glucose-dependent insulin release and reducing glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.

Oral tablet; take as prescribed, usually with meals to reduce stomach upset. Swallow whole with water; do not crush/chew. Regularly monitor blood glucose and follow diet/exercise advice.

Nausea, vomiting, diarrhea, abdominal pain, loss of appetite, headache, dizziness, upper respiratory tract infection, hypoglycaemia (more likely with other antidiabetics), metallic taste

Not for type 1 diabetes or diabetic ketoacidosis. Metformin can rarely cause lactic acidosis—risk increases with kidney impairment, dehydration, heavy alcohol use, severe infection, hypoxia/heart failure, or liver disease; seek urgent care for rapid breathing, severe weakness, abdominal pain, or unusual sleepiness. Avoid/withhold around iodinated contrast procedures and major surgery as advised. Monitor kidney function before and during therapy; use caution in elderly. Stop and consult doctor if pancreatitis symptoms occur (severe persistent abdominal pain), or if signs of hypersensitivity or hepatitis/jaundice appear.

Alcohol (increases lactic acidosis risk), iodinated contrast media, carbonic anhydrase inhibitors (e.g., topiramate, acetazolamide), cimetidine, diuretics, corticosteroids, thyroid hormones, sympathomimetics, rifampicin, ACE inhibitors, insulin/sulfonylureas (increased hypoglycaemia risk)

Store below 25°C in a cool, dry place. Protect from moisture and light. Keep out of reach of children.

Galvus Met 50/500 Tablet, Jalra M 50/500 Tablet, Zomelis Met 50/500 Tablet, Vilda M 50/500 Tablet, Vildamet 50/500 Tablet